Clinical trials: Metastasis Colorectal Cancer
Metastatic Colorectal Cancer
Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1
This study aims to use the corresponding pharmacogenetic analysis to increase the dose of irinotecan in the schemes commonly used standard chemotherapy in advanced colorectal cancer treatment first.
- Trial name
- FOLFIRI-AD (NCT01639326)
- Testing
- Irinotecan high doses, Irinotecan standard doses
- Where
- 3 sites in Spain
- Volunteers
- 96 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Colorectal Neoplasms
Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases
Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases
- Trial name
- CRLM (NCT07564908)
- Testing
- Formalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H&E) and Multiplex immunohistochemistry (mIHC) staining.
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Meng Qiu
Metastatic Colorectal Cancer
Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer
Colorectal cancer is the 2nd leading cause of cancer death in France. Its incidence is nearly 45,000 new cases per year in 2017, with an estimated 5-year survival of 63% in 2015.
- Trial name
- NCT05299840
- Testing
- Oncogramme results available, Oncogramme results unavailable
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Oncomedics
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.
EGFR-positive Colorectal Cancer
EGFR CART Cells for Patients With Metastatic Colorectal Cancer
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer.
- Trial name
- NCT03152435
- Testing
- EGFR CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Second People's Hospital
Colorectal Cancer Metastatic, MSI-H Colorectal Cancer
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.
NIPISAFE is open-label, phase II study to identify a combination scheme of nivolumab and ipilimumab with a high level of clinical activity, but with a lower toxicity in MSI/dMMR metastatic colorectal cancer patients.
- Trial name
- NIPISAFE (NCT04730544)
- Testing
- Nivolumab 480mg + Ipilimumab, Nivolumab 240 mg + Ipilimumab
- Where
- 19 sites in France
- Volunteers
- 96 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Colorectal Cancer
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine whether SCT200 is safe and tolerant in the treatment of metastatic colorectal cancer
- Trial name
- NCT02211443
- Testing
- Recombinant full human Anti-EGFR Monoclonal Antibody
- Volunteers
- 21 people
- Sponsor
- Sinocelltech Ltd.
Metastatic Colorectal Cancer
Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan
Primary Endpoint : To evaluate the Disease control rate (DCR) Secondary Endpoints: To evaluate the Progression-free survival (PFS), Overall survival(OS) and Safety profile
- Trial name
- NCT06495463
- Testing
- Trifluridine/tipiracil
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Chang Gung Memorial Hospital
Colorectal Cancer, ERAS
Compliance With ERAS and Five Year Survival After Colorectal Cancer Treatment
The Enhanced Recovery after Surgery (ERAS) protocol has transformed perioperative care, representing a significant paradigm shift in managing colorectal cancer patients.
- Trial name
- NCT06342687
- Testing
- High compliance with ERAS protocol
- Where
- Poland
- Volunteers
- 468 people
- Sponsor
- Jagiellonian University
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Colorectal Cancer
A Randomized, Prospective, Multicenter Study for the Role of Primary Tumor Resection in Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastasis
Short description for lay public, include brief statement of the study hypothesis
- Trial name
- NCT01978249
- Testing
- Systemic chemotherapy, primary tumor resection (PTR)
- Where
- 12 sites in South Korea
- Volunteers
- 52 people
- Sponsor
- Yonsei University
Metastatic Colorectal Cancer
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer
This is a personalized anti-cancer vaccine protocol which includes an in-situ (in the body) cancer vaccine step which combines killing a single metastatic tumor lesion by use of cryoablation in order to cause the release of…
- Trial name
- NCT01741038
- Testing
- AlloStim®, cryoablation, Physician's Choice (PC)
- Where
- Thailand
- Sponsor
- Mirror Biologics, Inc.
Metastatic Colorectal Cancer
"Cancersensor" Metastasis Resection
Observational, non randomized study aimed at measuring the effect of surgical resection of metastasis in the urinary concentrations of physiological modified nucleosides in 45 patients with metastatic colorectal cancer.
- Trial name
- NCT01693848
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Liver Neoplasms
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
This study will evaluate the safety and effects of vaccine treatment plus radiation to the liver in patients with solid tumors that have spread to the liver.
- Trial name
- NCT00081848
- Testing
- rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM, rF-CEA(6D)/TRICOM, Recombinant Fowlpox-GM-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
The purpose of this study is to assess the efficacy and safety of Cadonilimab (AK104) combined with chemotherapy and bevacizumab as first-line treatment for patients with RAS mutated or right sided-metastatic MSS colorectal cancer
- Trial name
- NCT06566755
- Testing
- Cadonilimab (AK104) combined with chemotherapy and bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Caigang Liu
Metastatic Colorectal Cancer
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment…
- Trial name
- NCT05694936
- Testing
- Sodium Valproate, Panitumumab, Cetuximab
- Where
- 12 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Colorectal Cancer, Peritoneal Metastases
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
- Conditions
- Colorectal Cancer, Peritoneal Metastases, Carcinomatosis
- Trial name
- NCT07411599
- Testing
- Cyclophosphamide, Fludarabine, Cetuximab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
- Trial name
- HORIZON III (NCT00384176)
- Testing
- Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX)
- Where
- 280 sites in United States, Australia and 26 more
- Volunteers
- 1,814 people
- Sponsor
- AstraZeneca
Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation
XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
- Trial name
- XS-03-II201 (NCT06936527)
- Testing
- Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI, Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Rectal Cancer, Lymph Node Metastases
FDG - PET / MRI in Patients With Rectal Cancer
The combination of FDG-PET/CT and MRI at staging of rectal cancer in diagnosis is currently very little studied. The investigator have a unique opportunity to study this.
- Trial name
- RECTOPET (NCT03846882)
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Västerbotten
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.